Lisata Therapeutics (LSTA) Competitors $2.48 +0.01 (+0.20%) Closing price 08/1/2025 03:54 PM EasternExtended Trading$2.50 +0.02 (+0.60%) As of 08/1/2025 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LSTA vs. ELUT, WHWK, ORMP, MGX, MIST, JMAC, INKT, EPIX, CABA, and QNCXShould you be buying Lisata Therapeutics stock or one of its competitors? The main competitors of Lisata Therapeutics include Elutia (ELUT), Whitehawk Therapeutics (WHWK), Oramed Pharmaceuticals (ORMP), Metagenomi (MGX), Milestone Pharmaceuticals (MIST), Maxpro Capital Acquisition (JMAC), MiNK Therapeutics (INKT), ESSA Pharma (EPIX), Cabaletta Bio (CABA), and Quince Therapeutics (QNCX). These companies are all part of the "pharmaceutical products" industry. Lisata Therapeutics vs. Its Competitors Elutia Whitehawk Therapeutics Oramed Pharmaceuticals Metagenomi Milestone Pharmaceuticals Maxpro Capital Acquisition MiNK Therapeutics ESSA Pharma Cabaletta Bio Quince Therapeutics Elutia (NASDAQ:ELUT) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends. Does the media prefer ELUT or LSTA? In the previous week, Elutia had 3 more articles in the media than Lisata Therapeutics. MarketBeat recorded 4 mentions for Elutia and 1 mentions for Lisata Therapeutics. Elutia's average media sentiment score of 0.44 beat Lisata Therapeutics' score of 0.00 indicating that Elutia is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elutia 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lisata Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders believe in ELUT or LSTA? 74.0% of Elutia shares are owned by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are owned by institutional investors. 27.6% of Elutia shares are owned by insiders. Comparatively, 9.6% of Lisata Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more volatility & risk, ELUT or LSTA? Elutia has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. Comparatively, Lisata Therapeutics has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Is ELUT or LSTA more profitable? Lisata Therapeutics has a net margin of 0.00% compared to Elutia's net margin of -168.23%. Elutia's return on equity of 0.00% beat Lisata Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Elutia-168.23% N/A -96.70% Lisata Therapeutics N/A -61.37%-53.35% Which has stronger valuation and earnings, ELUT or LSTA? Lisata Therapeutics has lower revenue, but higher earnings than Elutia. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioElutia$24.38M3.44-$53.95M-$1.93-1.06Lisata Therapeutics$1M21.41-$19.99M-$2.30-1.08 Do analysts recommend ELUT or LSTA? Elutia currently has a consensus price target of $8.00, indicating a potential upside of 292.16%. Lisata Therapeutics has a consensus price target of $23.50, indicating a potential upside of 845.67%. Given Lisata Therapeutics' higher probable upside, analysts plainly believe Lisata Therapeutics is more favorable than Elutia.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Elutia 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Lisata Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryElutia beats Lisata Therapeutics on 8 of the 14 factors compared between the two stocks. Get Lisata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LSTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LSTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LSTA vs. The Competition Export to ExcelMetricLisata TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.37M$2.99B$5.48B$9.54BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-1.0817.7428.8623.83Price / Sales21.41178.75371.7266.14Price / CashN/A41.9535.4557.96Price / Book0.718.508.275.54Net Income-$19.99M-$55.06M$3.25B$259.28M7 Day Performance-7.62%-3.99%-3.73%-4.68%1 Month Performance-8.97%9.58%4.29%4.36%1 Year Performance-22.59%6.70%25.87%17.89% Lisata Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LSTALisata Therapeutics2.314 of 5 stars$2.49+0.2%$23.50+845.7%-24.7%$21.37M$1M-1.0830Gap DownELUTElutia3.452 of 5 stars$2.15+0.7%$8.00+273.0%-40.4%$88.19M$23.71M-1.11180News CoverageUpcoming EarningsGap DownWHWKWhitehawk TherapeuticsN/A$1.85flatN/AN/A$87.15M$25.98M11.5640ORMPOramed Pharmaceuticals0.5957 of 5 stars$2.12-0.2%N/A-10.5%$86.39M$2M-4.8110News CoveragePositive NewsAnalyst RevisionMGXMetagenomi2.4384 of 5 stars$2.30+5.8%$13.00+466.4%-35.7%$85.04M$52.29M-1.08236Positive NewsMISTMilestone Pharmaceuticals1.8266 of 5 stars$1.59+6.4%$7.00+341.6%+2.9%$84.20M$1M-2.0230Positive NewsUpcoming EarningsShort Interest ↑JMACMaxpro Capital AcquisitionN/A$6.21-3.7%N/A+2,963.2%$83.39MN/A0.002,021News CoverageINKTMiNK Therapeutics2.4694 of 5 stars$20.75+4.8%$37.50+80.7%+63.9%$83.35MN/A-8.2930Positive NewsShort Interest ↑EPIXESSA Pharma1.1894 of 5 stars$1.88+0.3%$2.00+6.7%-63.4%$83.23MN/A-2.9850News CoverageUpcoming EarningsCABACabaletta Bio1.8014 of 5 stars$1.64-0.3%$14.43+782.5%-79.1%$82.96MN/A-0.6450Upcoming EarningsQNCXQuince Therapeutics2.4373 of 5 stars$1.80-5.1%$8.00+343.5%+125.9%$80.48MN/A-1.2760Negative NewsShort Interest ↑ Related Companies and Tools Related Companies Elutia Competitors Whitehawk Therapeutics Competitors Oramed Pharmaceuticals Competitors Metagenomi Competitors Milestone Pharmaceuticals Competitors Maxpro Capital Acquisition Competitors MiNK Therapeutics Competitors ESSA Pharma Competitors Cabaletta Bio Competitors Quince Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LSTA) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lisata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lisata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
